The aim of this project is to develop a tumour profiling assay based on targeted multiplexed enrichment and next generation sequencing (NGS) of clinically informative genes and variants. Oxford Gene Technology (OGT) will work closely with its partners in Birmingham and Southampton, and the CR-UK Technology hubs to build the assay into an innovative, integrated workflow, from sample submission to interpretation of the patient tumour profile. As a final step, the data will be transferred into an automated prescription management system, developed by CIS Oncology, which will enable the output of the profiling to be closely coupled to drug prescription, ensuring accuracy and consistency of care and delivering significant cost savings to the NHS. OGT will investigate the potential, not just to commercialise the assay panel, but also to offer a centralised, high-throughput, validated service run from OGT's accredited laboratories.